Full text not available from this repository.

Abstract

Rheumatoid arthritis is a leading musculoskeletal cause of disability in Western society. Therapeutic options have expanded rapidly with the advent of biological agents as treatment options. One of these, tocilizumab, targets the interleukin-6 receptor and has been approved since the late 2000s in many jurisdictions. This approval was based on 6-12 month trials. It is now appropriate to look at longer-term studies and what new insights they have provided into this agent. Data are based largely on observational studies with their well-known limitations as well as some further randomized trials and provide a number of important observations regarding both efficacy and safety. In conclusion, the longer-term data suggest tocilizumab efficacy increases over time for both signs and symptoms and radiographic change. It is also corticosteroid sparing. The safety data are consistent with the shorter-term trials and are largely reassuring but some questions still remain over cardiovascular safety and cancer risk.

Item Type:	Article
Authors/Creators:	Jones, G and Panova, E
Keywords:	cohort, database, long term, rheumatoid, tocilizumab, trials
Journal or Publication Title:	Therapeutic Advances in Musculoskeletal Disease
Publisher:	Sage Publications Ltd.
ISSN:	1759-720X
DOI / ID Number:	10.1177/1759720X18798462
Copyright Information:	Copyright 2018 The Authors
Related URLs:	Google Scholar: Jones, G UTAS Profile: Jones, G
Item Statistics:	View statistics for this item

Actions (login required)

Item Control Page